Eli Lilly and Company $LLY Stock Position Raised by Becker Capital Management Inc.

Becker Capital Management Inc. lifted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 372.4% during the second quarter, Holdings Channel reports. The firm owned 20,324 shares of the company’s stock after buying an additional 16,022 shares during the period. Becker Capital Management Inc.’s holdings in Eli Lilly and Company were worth $15,843,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. BNP Paribas grew its position in shares of Eli Lilly and Company by 0.4% during the second quarter. BNP Paribas now owns 36,639 shares of the company’s stock worth $28,548,000 after acquiring an additional 164 shares during the last quarter. Sei Investments Co. boosted its stake in Eli Lilly and Company by 25.9% during the 2nd quarter. Sei Investments Co. now owns 669,332 shares of the company’s stock valued at $521,779,000 after purchasing an additional 137,785 shares during the period. Frisch Financial Group Inc. grew its position in Eli Lilly and Company by 32.1% in the 2nd quarter. Frisch Financial Group Inc. now owns 2,782 shares of the company’s stock worth $2,169,000 after purchasing an additional 676 shares during the last quarter. Marathon Capital Management increased its stake in shares of Eli Lilly and Company by 21.2% in the second quarter. Marathon Capital Management now owns 2,576 shares of the company’s stock valued at $2,008,000 after purchasing an additional 450 shares during the period. Finally, Nebula Research & Development LLC bought a new stake in shares of Eli Lilly and Company during the second quarter valued at approximately $749,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 1.1%

LLY stock opened at $993.51 on Thursday. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm has a market capitalization of $939.25 billion, a P/E ratio of 48.61, a P/E/G ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,111.99. The company’s 50 day simple moving average is $931.98 and its 200-day simple moving average is $815.46.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The company’s revenue was up 53.9% on a year-over-year basis. During the same period in the previous year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company’s payout ratio is presently 29.35%.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Truist Financial lifted their target price on Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research note on Wednesday, November 19th. JPMorgan Chase & Co. lifted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,150.00 and gave the company an “overweight” rating in a research note on Tuesday, November 18th. Morgan Stanley increased their target price on shares of Eli Lilly and Company from $1,171.00 to $1,290.00 and gave the company an “overweight” rating in a research report on Monday, November 24th. Leerink Partnrs upgraded shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Monday, November 10th. Finally, The Goldman Sachs Group increased their price objective on shares of Eli Lilly and Company from $876.00 to $879.00 and gave the company a “buy” rating in a report on Friday, October 10th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,109.24.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.